Adriann Sax | CEO, Orsenix LLC

Adrainn-SaxMs. Sax has been an advocate and practitioner of innovative thinking and strategic growth for the pharmaceutical industry over her 25+ year career leading Strategy, Business Development and Commercial Initiatives globally in pharmaceuticals, biotech and devices. She served as Executive Vice President, Chief Commercial Officer of Kadmon. Prior to Kadmon, Ms. Sax was Chief Business Officer of Symphogen A/S, focusing on corporate development, marketing and communications and establishing that company’s presence in North America. Prior to Symphogen, Ms. Sax held the role of Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals. She has also held leadership roles at Merck, Bristol-Myers Squibb, Roche Laboratories and Sterling Drug, making important contributions in the areas of oncology, transplantation and diagnostic imaging. Ms. Sax serves as a Director on the National Advisory Board of the Healthcare Businesswomen’s Association and Foundation Associate of the Women Business Leaders of the U.S. Healthcare Foundation. In 2008, Adriann was named as one of the Top 100 Most Inspiring Leaders in the Life Sciences Industry by PharmaVoice Magazine. Ms. Sax holds an MBA in Marketing and Finance from the Keller Graduate School of Management and a BS in Veterinary Medicine from the University of Delaware.